Liver News and Research

RSS

Health risk associated with harmful substances in food may be underestimated

Mice are often used to test whether substances in food are harmful to humans. This requires that mice and humans metabolise substances in the same way. Humans have certain enzymes in more parts of the body than mice. The health risk associated with harmful substances in food may therefore be underestimated.

2 Nov 2011

Researchers develop new 3D bone marrow culture systems

Stromal cells, as distinct from hematopoietic cells, are an essential component of the bone marrow microenvironment and are necessary for the long-term maintenance of hematopoietic stem cells (HSCs) in vitro.

2 Nov 2011

Studies on effectiveness of new HCV therapies presented at 76th ACG meeting

Studies reporting on the effectiveness of new therapies for chronic Hepatitis C virus are among the clinical science presented at the American College of Gastroenterology's 76th Annual Scientific Meeting, where investigators also presented findings from an age-based risk assessment and screening intervention for Hepatitis C among Baby Boomers, patients aged 50-65, who saw a gastroenterologist for routine colon cancer screening.

1 Nov 2011

NPS announces new data from GATTEX Phase 3 study on short bowel syndrome

NPS Pharmaceuticals, Inc., a specialty pharmaceutical company developing innovative therapeutics for rare gastrointestinal and endocrine disorders, today announced new data from STEPS 2, a long-term open-label study, showing that GATTEX (teduglutide) was associated with achieving and maintaining clinically meaningful reductions in parenteral nutrition (PN) and intravenous (IV) fluid volume in adult subjects with short bowel syndrome.

1 Nov 2011

Astex to present data on direct acting antiviral agents against HCV at 62nd AASLD meeting

Astex Pharmaceuticals, Inc., a pharmaceutical company dedicated to the discovery, development and commercialization of novel therapeutics, announced that it will present data on its novel, first-in-class direct acting antiviral agents (DAA) against Hepatitis C Virus (HCV) at the 62nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in San Francisco, November 4-8, 2011.

31 Oct 2011

Researchers shed light on inner workings of endocycle

An international team of researchers led by investigators in the U.S. and Germany has shed light on the inner workings of the endocycle, a common cell cycle that fuels growth in plants, animals and some human tissues and is responsible for generating up to half of the Earth's biomass.

31 Oct 2011

Researchers uncover biochemical signals that trigger generation of new lung alveoli

Researchers at Weill Cornell Medical College say they have taken an important step forward in their quest to "turn on" lung regeneration -- an advance that could effectively treat millions of people suffering from respiratory disorders.

29 Oct 2011

NHS must plan to deal with predicted 45% leap in new cancer cases

The NHS must start planning now to deal with a predicted leap of 45 per cent in the number of new cancer cases in the UK over the next two decades, Cancer Research UK warns today (Friday).

28 Oct 2011

Potential avenue to make an unhealthy heart grow more like a healthy version

Identification of three fatty acids involved in the extreme growth of Burmese pythons' hearts following large meals could prove beneficial in treating diseased human hearts, according to research co-authored by a University of Alabama scientist and publishing in the Oct. 28 issue of Science.

28 Oct 2011

Novel stem cells method may eliminate need for antirejection drugs in transplants

Surgical researchers at the University of Washington, Seattle, have pioneered a method using stem cells that may one day eliminate the need for antirejection drugs in transplants. Primary investigator David Mathes, MD, FACS, and his research fellow Jeff Chang, MD, MS, presented their findings today at the 2011 Clinical Congress of the American College Surgeons.

28 Oct 2011

Adult stem cells can reshape our organs in response to environmental change

A new study from University of California, Berkeley, researchers demonstrates that adult stem cells can reshape our organs in response to changes in the body and the environment, a finding that could have implications for diabetes and obesity.

28 Oct 2011

FDA responds to Delcath's request for pre-NDA meeting

Delcath Systems, Inc. announced today that the U.S. Food and Drug Administration (FDA) has responded to the Company's request made in September for a pre-New Drug Application (NDA) meeting and has scheduled a date in mid-January 2012.

27 Oct 2011

Insulin resistance paradox

Obesity and insulin resistance are almost inevitably associated with increases in lipid accumulation in the liver, a serious disease that can deteriorate to hepatitis and liver failure. A real paradox in understanding insulin resistance is figuring out why insulin-resistant livers make more fat. Insulin resistance occurs when the body does a poor job of lowering blood sugars.

27 Oct 2011

Research questions aromatherapy safety

Aromatherapy oils are relied upon to relax, reduce stress and soothe aches and pains by many. However researchers from Chia-Nan University of Pharmacy and Science Tainan, Taiwan say these oils may not be completely harmless.

24 Oct 2011

Three dry days a week reduces risk of alcohol related liver disease

The Royal College of Physicians said the present official guidance on healthy drinking limits is ‘extremely dangerous’ and must be rewritten – because it implies that drinking every day is fine. Government advice states men should drink no more than four units a day and women no more than three.

24 Oct 2011

CryoLife begins enrollment in BioFoam Surgical Matrix IDE clinical trial

CryoLife, Inc.,, a leading tissue processing and medical device Company focused on cardiac and vascular surgery, today announced that it has enrolled the first patient in its U.S. Investigational Device Exemption (IDE) clinical trial for its BioFoam® Surgical Matrix protein hydrogel technology. In connection with the trial, BioFoam will be used as an adjunct to conservative measures of achieving hemostasis on newly resected liver parenchyma.

24 Oct 2011

Vertex initiates INCIVEK combination Phase 3b study for hepatitis C

Vertex Pharmaceuticals Incorporated today announced the initiation of a Phase 3b study called CONCISE that will evaluate the potential for treatment with INCIVEK (telaprevir) combination therapy to be shortened to 12 weeks in people with genotype 1 chronic hepatitis C who have the 'CC' variation near the IL28B gene.

24 Oct 2011

Mirna, Silence enter agreement to assess delivery systems for novel microRNAs

Silence Therapeutics plc, a leading RNA interference (RNAi) therapeutics company, today announced that it has entered into an agreement with Mirna Therapeutics Inc., a biopharmaceutical company pioneering microRNA-based therapeutics for cancer, to assess the delivery capabilities of Silence's proprietary AtuPLEX and DBTC delivery systems for Mirna's novel microRNAs.

24 Oct 2011

SCI patients with autonomic dysfunction more likely to develop heart disease

New research from the Heart and Stroke Foundation and the Christopher and Dana Reeve Foundation may help explain why people with spinal cord injury (SCI) have a higher risk of developing heart disease.

24 Oct 2011

C. sinensis parasite lacks enzymes required for fatty acid biosynthesis

The human liver fluke Clonorchis sinensis affects more than 35 million people in South East Asia and 15 million in China. Infection by this parasite causes clonorchiasis. Repeated or chronic infection can lead to serious disease of the liver, gall bladder or bile ducts, including the frequently fatal bile duct cancer - cholangiocarcinoma.

24 Oct 2011